Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880958 | 0.89 | CA2 (0.41) | ALDH1A1PKMTDP1CA2 | |
| SCHEMBL25881122 | 0.81 | KMT2A (0.42) | ALDH1A1PKMTDP1KDM4E | |
| SCHEMBL25880955 | 0.78 | ALDH1A1 (0.39) | ALDH1A1PKMTDP1 | |
| SCHEMBL25881070 | 0.76 | ALDH1A1 (0.40) | ALDH1A1PKMTDP1KDM4ESMN1; SMN2 | |
| SCHEMBL25889848 | 0.70 | ALDH1A1 (0.33) | ALDH1A1PKM | |
| SCHEMBL28561383 | 0.69 | KMT2A (0.48) | ALDH1A1TDP1KDM4ESMN1; SMN2 | |
| SCHEMBL31201645 | 0.69 | ALDH1A1 (0.47) | ALDH1A1PKMTDP1KDM4ESMN1; SMN2 | |
| SCHEMBL2768889 | 0.68 | CA12 (0.33) | CA2KDM4E | |
| SCHEMBL25880959 | 0.68 | DUT (0.33) | ALDH1A1PKM | |
| SCHEMBL21752097 | 0.65 | TDP1 (0.41) | ALDH1A1PKMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2167196-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1963324-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007071936-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | ALDH1A1 4483/4885PKM 3649/4885TDP1 2504/4885 |
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | ALDH1A1 4233/4885PKM 2340/4885TDP1 2288/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | ALDH1A1 4225/4885PKM 2306/4885TDP1 3642/4885 |
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | ALDH1A1 4225/4885PKM 2306/4885TDP1 3642/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | ALDH1A1 1245/4885PKM 1374/4885TDP1 3283/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | ALDH1A1 1320/4885PKM 527/4885TDP1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.